KSI-3716

小分子

KSI-3716

K655583-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

KSI-3716 is a potent c-Myc inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer In Vitro KSI-3716 blocks c-MYC/MAX from forming a complex with target gene promoters. KSI-3716 effectively blocks complex formation in a dose dependent manner (IC 50 =0.84 μM). c-MYC mediated transcriptional activity is inhibited by KSI-3716 at concentrations as low as 1 μM. The expression of c-MYC target genes, such as cyclin D2, CDK4 and hTERT, is markedly decreased. KSI-3716 exerts cytotoxic effects on bladder cancer cells by inducing cell cycle arrest and apoptosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Intravesical instillation of KSI-3716 at a dose of 5 mg/kg significantly suppresses tumor growth with minimal systemic toxicity . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:c-Myc

KSI-3716 是一种强效的 c-Myc 抑制剂，可阻断 c-MYC/MAX 与靶基因启动子的结合。KSI-3716 是一种有效的膀胱癌膀胱内化疗药物。

1151813-61-4(DMSO)

C17H11BrCl2N2O2

426.09 g/mol

CC(=O)C1=C(NC2=C(C=CC(=C2C1=O)Cl)Br)NC3=CC=C(C=C3)Cl